A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma
Biomolecules and Biomedicine · 2023
DOI: 10.17305/bb.2022.8481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2023. Verfasst von Chunlan Hou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cuproptosis, a copper-induced mechanism of mitochondrial-related cell death, has been implicated as a breakthrough in the treatment of cancer and has become a new treatment strategy. Furthermore, long non-coding RNA (lncRNA) can change the biological activities of tumor cells. Worldwide, lung squamous cell carcinoma (LUSC) is among the most common annoying tumors. LncRNAs related to cuproptosis are not researched at LUSC. Our research intends to develop a signature on the basis of cuproptosis-associated lncRNAs, which can predict LUSC prognosis and investigate LUSC immunological features. The TCGA database was used to retrieve LUSC transcriptome, clinical, and gene mutation data. For statistical analysis, we utilized the R program. We created a signature consisting of three cuproptosis-related lncRNAs in this investigation (including AC002467.1, LINC01740, and LINC02345). Survival analyses and Receiver Operating Characteristic curves demonstrated that this signature possessed powerful predictive capability. The signature’s ability to predict was confirmed by a Receiver Operating Characteristic curve and principal component analysis. Notably, the patient with a high-risk score and a high tumor mutation burden level had a lower survival time. Furthermore, the tumor immune dysfunction and exclusion analysis showed that these individuals with low-risk scores may benefit from immunotherapy. The signature constructed by three cuproptosis-associated lncRNAs may be prognostic markers of LUSC. It contributes to immunotherapy and offers LUSC’s therapy a new treatment direction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
- Department of Cardiothoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
- Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Zitieren
APA
Hou, C., Wu, X., Li, C., Wang, C., Liu, J., & Luo, Q. (2023). A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2022.8481
Vancouver
Hou C, Wu X, Li C, Wang C, Liu J, Luo Q. A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma. Biomolecules and Biomedicine. 2023. doi:10.17305/bb.2022.8481
BibTeX
@article{Hou2023,
author = {Hou, Chunlan and Wu, Xiuping and Li, Caoyang and Wang, Chao and Liu, Jinbo and Luo, Qing},
title = {A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma},
journal = {Biomolecules and Biomedicine},
year = {2023},
doi = {10.17305/bb.2022.8481}
}
EUVIMED